Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients

British Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2008, Pages 646-652

  Brown, Morris J ^a   Toal, Corey B ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c Bayer Inc   (Canada)

Author keywords

Crossover trial; Formulation; Nifedipine

Indexed keywords

CORACTEN XL; NIFEDIPINE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG RESPONSE; ENCAPSULATION; FEMALE; GASTROINTESTINAL THERAPEUTIC SYSTEM; HEART RATE; HUMAN; HYPERTENSION; LONG ACTING FORMULATION; MALE; NORADRENALIN BLOOD LEVEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; NOREPINEPHRINE; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 42149176532     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03082.x     Document Type: Article

References (17)

1. Schug BS, Brendel E, Wolf D, Wonnemann M, Wargenau M, Blume HH. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed I the European Union. Eur J Pharmaceut Sci 2002 15 : 279 85.
2. Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH. Dosage form related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 2002 58 : 119 25.
3. Abrahamsson B, Alpsten M, Bake B, Jonsson UE, Eriksson-Lepkowska M, Larsson A. Drug absorption from nifedipine hydrophilic matrix-extended release (ER) tablet - comparison with an osmotic pump tablet and effect of food. J Control Rel 1998 52 : 301 10.
4. Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 2002 53 : 582 8.
5. Wonnemann M, Schug B, Schmucker K, Brendel E, van Zwieten PA, Blume H. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. Int J Clin Pharmacol Ther 2006 44 : 38 48.
6. Swanson DR, Barclay BL, Wong P, Theeuwes F. Nifedipine Gastrointestinal Therapeutic System. Am J Med 1987 83 (Suppl. 6B 3 9.
7. Myers MG, Raemsch KD. Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. J Cardiovasc Pharmacol 1987 10 (Suppl. 10 S76 8.
8. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokinet 1992 22 : 416 33.
9. Yamashita S. Calcium channel blockers: current controversies in cardiovascular therapy. Pharm Pract 1996 3 : 1 8.
10. Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984 35 : 742 9.
11. Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid JL. Nifedipine: individual responses and concentration-effect relationships. Hypertension 1988 12 : 443 9.
12. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high performance liquid chromatography with electrochemical detection. J Chromatogr B 1994 653 : 131 8.
13. Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal system: a controlled release formulation of Nifedipine. Am J Med 1987 83 (Suppl. 6B 10 4.
14. Toal CB, Laplante L. Is there a difference in hypertensive patient compliance between a once a day or twice a day Nifedipine. Am J Hypertens 1995 8 : 71A.
15. Rayner B, Buchanan-Lee B, Brink J, Opie L. Generic substitution - is it safe in patients at high cardiovascular risk? S Afr Med J 2002 92 : 603 4.
16. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990 48 : 676 85.
17. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002 62 : 1481 502.